Ivy Natal

Ivy Natal is a biotechnology startup based in the United States, founded in 2020. The company's mission, as encapsulated in their slogan "Unlocking human fertility," addresses a significant need in the biotechnology and healthcare industries. Ivy Natal aims to revolutionize the way people perceive and approach fertility. Their innovative approach to enabling women who cannot have children through traditional means to have genetic offspring is truly groundbreaking.

Through a process that begins with a simple skin biopsy, Ivy Natal leverages a technique that activates the skin cell's existing DNA to transform it into a viable egg cell. This method circumvents the challenges associated with conventional approaches to producing eggs and sperm in vitro. By enabling women to have genetic children, the company not only offers hope and opportunity to individuals facing infertility due to various reasons such as surgery, chemotherapy, age, or genetic conditions but also empowers them to make choices about their fertility.

The latest major milestone for Ivy Natal was a $1.50M Venture Round investment on 01 January 2022, with Alameda Research as the investor. This investment underscores the support and confidence of industry players in the company's vision and technology. The potential for disrupting the conventional approaches to fertility treatments and the significant social impact of their mission make Ivy Natal a compelling venture for investors looking to support innovative and socially impactful startups in the biotechnology and healthcare sectors.

By combining technological innovation with a clear societal need, Ivy Natal provides an opportunity for investors to participate in a venture that not only has the potential for substantial financial returns but also offers the promise of fundamentally changing the landscape of fertility treatment and choice.